Pharmacodynamic effects of the oral glucokinase activator AZD6370 after single doses in healthy volunteers assessed with euglycaemic clamp.
about
Investigational anti-hyperglycemic agents: the future of type 2 diabetes therapy?Chronic glucokinase activator treatment at clinically translatable exposures gives durable glucose lowering in two animal models of type 2 diabetes.A patent review of glucokinase activators and disruptors of the glucokinase--glucokinase regulatory protein interaction: 2011-2014.Characterization of the heterozygous glucokinase knockout mouse as a translational disease model for glucose control in type 2 diabetes.Preclinical PK/PD modeling and human efficacious dose projection for a glucokinase activator in the treatment of diabetes.
P2860
Pharmacodynamic effects of the oral glucokinase activator AZD6370 after single doses in healthy volunteers assessed with euglycaemic clamp.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Pharmacodynamic effects of the ...... sessed with euglycaemic clamp.
@en
Pharmacodynamic effects of the ...... sessed with euglycaemic clamp.
@nl
type
label
Pharmacodynamic effects of the ...... sessed with euglycaemic clamp.
@en
Pharmacodynamic effects of the ...... sessed with euglycaemic clamp.
@nl
prefLabel
Pharmacodynamic effects of the ...... sessed with euglycaemic clamp.
@en
Pharmacodynamic effects of the ...... sessed with euglycaemic clamp.
@nl
P2093
P2860
P1476
Pharmacodynamic effects of the ...... sessed with euglycaemic clamp.
@en
P2093
H Ericsson
J W Eriksson
M Hartford
M Sjöstrand
P2860
P356
10.1111/J.1463-1326.2012.01672.X
P577
2012-09-09T00:00:00Z